The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,435.00
Bid: 1,454.00
Ask: 1,456.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.138%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,435.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

16 Jul 2020 13:00

RNS Number : 2368T
Indivior PLC
16 July 2020
 

 

Indivior to Announce First Half and Second Quarter 2020 Results on July 30th and Host Conference Call Presentation

 

Slough, UK, and Richmond, VA, 16 July 2020 - Indivior PLC (LON: INDV) today announced that it will release its first half and second quarter 2020 results on July 30th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.

 

Key members of Indivior's leadership team led by Mark Crossley, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12:00 p.m. London time (7:00 a.m. U.S. Eastern).

 

Access the Live Webcast / Call for the Results on July 30th

The live webcast event will be available on the "Investors" section of the company's website at www.indivior.com. The webcast link is https://edge.media-server.com/mmc/p/ot3s33ij. Participants also may access the results presentation telephonically: US participants 1-631-510-7495; international participants +44 (0) 2071 928000. Please reference confirmation number 6735858. A replay of the presentation will be available at www.indivior.com.

 

About IndiviorIndivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

 

Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or jason.thompson@indivior.com

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NOREAEXKFEXEEFA
Date   Source Headline
23rd Nov 20237:00 amRNSTransaction in Own Shares
22nd Nov 20237:00 amRNSDirector/PDMR Shareholding
22nd Nov 20237:00 amRNSTransaction in Own Shares
21st Nov 202311:51 amRNSDirector/PDMR Shareholding
21st Nov 20237:00 amRNSTransaction in Own Shares
20th Nov 20233:33 pmRNSDirector/PDMR Shareholding
20th Nov 20232:55 pmRNSIndivior to Participate in Upcoming Investor Event
20th Nov 202312:56 pmRNSDirector/PDMR Shareholding
20th Nov 20239:37 amRNSHolding(s) in Company
17th Nov 202311:37 amRNSShare Repurchase Program
17th Nov 202310:00 amRNSHolding(s) in Company
17th Nov 20239:59 amRNSHolding(s) in Company
17th Nov 20237:00 amRNSAmendment to Relationship Agreement with Scopia
16th Nov 20232:00 pmRNSIndivior to Participate in Upcoming Conference
15th Nov 20232:54 pmRNSHolding(s) in Company
15th Nov 202310:23 amRNSHolding(s) in Company
10th Nov 202310:17 amRNSBlock listing Interim Review
9th Nov 20237:01 amRNSAppointment of Independent Non-Executive Director
9th Nov 20237:00 amRNS3rd Quarter Results
1st Nov 20234:00 pmRNSIndivior to Participate in Upcoming Conference
26th Oct 202311:51 amRNSHolding(s) in Company
23rd Oct 20237:00 amRNSIndivior settles Antitrust MDL with DPs
13th Oct 202312:14 pmRNSHolding(s) in Company
5th Oct 20233:30 pmRNSNotice of Results
21st Aug 20237:00 amRNSIndivior settles Antitrust MDL with End Payors
1st Aug 20234:00 pmRNSTotal Voting Rights
27th Jul 20237:00 amRNSHalf-year Report
26th Jul 20234:00 pmRNSHolding(s) in Company
24th Jul 20234:00 pmRNSHolding(s) in Company
10th Jul 20234:00 pmRNSHolding(s) in Company
5th Jul 20234:00 pmRNSHolding(s) in Company
30th Jun 20234:00 pmRNSDirector Declaration
29th Jun 20234:00 pmRNSHolding(s) in Company
27th Jun 202311:00 amRNSNotice of Results
21st Jun 20234:00 pmRNSHolding(s) in Company
16th Jun 20234:00 pmRNSHolding(s) in Company
15th Jun 20234:00 pmRNSHolding(s) in Company
14th Jun 20234:00 pmRNSHolding(s) in Company
14th Jun 20234:00 pmRNSHolding(s) in Company
13th Jun 20234:00 pmRNSHolding(s) in Company
12th Jun 20237:00 amRNSIndivior to Commence Trading on Nasdaq
7th Jun 20233:45 pmRNSHolding(s) in Company
2nd Jun 20235:17 pmRNSIndivior settles antitrust MDL with states and DC
1st Jun 20239:11 amRNSTotal Voting Rights
26th May 20234:20 pmRNSHolding(s) in Company
25th May 20232:30 pmRNSIndivior to Participate in Upcoming Conferences
24th May 20233:05 pmRNSHolding(s) in Company
23rd May 20236:05 pmRNSIndivior Files Form 20-F for US Listing
23rd May 20232:42 pmRNSHolding(s) in Company
23rd May 20238:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.